Mielot F, Danel P, Boyer C, Coulombel L, Dommergues J P, Tchernia G, Larrieu M J
Arch Fr Pediatr. 1987 Mar;44(3):161-5.
Fourteen children treated by L-Asparaginase for acute lymphoblastic leukemia had sequential coagulation studies performed including cephalin-kaolin time, Quick time, fibrinogen, factors II, VII + X and V, as well as antithrombin III and protein C, the major coagulation inhibitors. A severe antithrombin III and protein C deficiency was observed during therapy, with a coexisting hypocoagulability. This equilibrium partially explains the lack of thrombo-embolic phenomena in these children, despite the risk factors present. Although no substitutive therapy was instituted in these cases, their use in high-risk cases is discussed.
14名接受L-天冬酰胺酶治疗急性淋巴细胞白血病的儿童进行了一系列凝血研究，包括脑磷脂-高岭土时间、奎克氏凝血时间、纤维蛋白原、因子II、VII + X和V，以及主要的凝血抑制剂抗凝血酶III和蛋白C。治疗期间观察到严重的抗凝血酶III和蛋白C缺乏，并伴有低凝性。这种平衡部分解释了尽管存在危险因素，但这些儿童为何没有血栓栓塞现象。虽然这些病例未进行替代治疗，但讨论了其在高危病例中的应用。
